El fundador y director ejecutivo de Tempus AI (NASDAQ:TEM), Eric Lefkofsky, dijo que el desempeño de la compañía en el segundo trimestre estuvo respaldado por la demanda continua de perfiles genómicos integrales y el crecimiento de su negocio de licencias de datos. En su intervención en la Conferencia Global de Atención Médica de Morgan Stanley, Lefkofsky dijo que el diagnóstico

Tempus AI, Hut 8, SentinelOne, Upstart, and SoundHound AI are the five Artificial Intelligence stocks to watch today, according to MarketBeat

On September 9, Tempus AI (NASDAQ:TEM) said ARPA-H, a US health research agency, picked it to build an AI that treats heart failure patients without a clinician stepping in. The award is worth up to $9.5 million, which is small change for a company booking hundreds of millions in quarterly sales. But the dollars are […]

Tempus AI (TEM) has put a new data project at the center of the story. The business plans a research platform built on 100,000 whole genomes linked to long term clinical records. Tempus AI’s new whole genome project arrives after a sharp run in the shares, with a 90 day share price return of 62.68% and a 7 day gain of 31.91%. However, the 1 year total shareholder return of an 11.79% decline shows the longer term picture has been more mixed despite the current momentum around the US$77.84...

Discover how Tempus AI’s Q2 profit hinged on a $98.5M securities gain, what drives TEM stock, and how you can trade TEM perpetual futures. Explore more here.

Much of the optimism around TEM stems from Tempus’s agreement last month to buy Personalis for $1.5 billion.Personalis’s tools identify unique markers in a patient’s cancer cells, enabling Moderna to craft a custom mRNA vaccine that targets those exact fe

Earlier this month, Tempus AI announced a multi‑year initiative to build a research platform of 100,000 whole genomes linked to longitudinal clinical, imaging, pathology and outcome data, with plans to eventually scale toward one million genomes and offer broad access via its Tempus Lens environment by mid‑2027. This move extends Tempus AI beyond targeted panels into whole‑genome sequencing, creating a model‑ready, multimodal dataset specifically tailored for AI‑driven disease and drug...

Tempus AI (NasdaqGS:TEM) announced a new whole-genome sequencing initiative linked to clinical data for AI research in September 2026. The project aims to create a de-identified multimodal dataset that connects full genome reads with real-world clinical and imaging records. Management targets scaling the platform to one million whole genomes tied to patient outcomes for use in drug development and personalized care. This new whole-genome sequencing and clinical data platform comes against a...

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CAO Ryan Bartolucci sold 7,062 shares of the business

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Ryan Fukushima sold 700 shares of Tempus AI stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $70.00, for a total transaction of $49,000.00. Following the transaction, the chief executive officer directly owned 15,874 shares in the company, valued at approximately $1,111,180. This trade represents a 4.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.